The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequency of second- and third-line treatment among elderly Medicare stage IV colon cancer patients.
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech; Mitsubishi; Novartis; Pfizer; Sanofi
Research Funding - Bayer; FDA; NHLBI; NIA; NPC; PCORI; Pfizer; Sanofi
Kaloyan A Bikov
Research Funding - Bayer
Ebere Onukwugha
Research Funding - Bayer; Novartis; Pfizer; Sanofi
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Nader Hanna
Research Funding - Bayer